First AD

Second AD

Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Immuno-Oncology

Drs Leonard Gomella and Daniel Petrylak

OncLive News Network®

MAINSAIL: Lessons Learned

When to Image: Earlier?

Looking Forward: Immunotherapy and Genomics

Abiraterone: Approval and Use

Sequencing: Important Question With Many Answers

A Review of Bone-Targeted Therapies

Changes in NCCN Guideline: Affecting Second-Line

Sipuleucel-T: Evidence-based Use

Considerations in Treatment Selection

Changes in NCCN Guideline: Affecting First-Line

Prostate Cancer: Which Guidelines